Abiraterone + ADT vs ADT only: Time to death from prostate cancerMedian
Abiraterone + ADT probably leads to lower time to death due to prostate cancer measured at a median compared with ADT alone (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Abiraterone + ADT vs ADT alone Time to death due to prostate cancer measured at a median · men with metastatic, hormone‐sensitive prostate cancer Abiraterone + ADT probably leads to lower time to death due to prostate cancer measured at a median compared with ADT alone (moderate certainty). Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation… (2020) · Cochrane Headline outcomes only | HR 0.58 [0.5, 0.68] | 2 studies · 2201 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic… 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.